Proprotein Convertase Subtilisin & Kexin Type 9 Industry Research Report 2025
Description
Summary
According to APO Research, The global Proprotein Convertase Subtilisin & Kexin Type 9 market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Proprotein Convertase Subtilisin & Kexin Type 9 is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Proprotein Convertase Subtilisin & Kexin Type 9 is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Proprotein Convertase Subtilisin & Kexin Type 9 is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Proprotein Convertase Subtilisin & Kexin Type 9 include Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, Novartis AG, Eli Lilly and Co, Pfizer Inc, The Medicines Company, Serometrix LLC, Regeneron Pharmaceuticals Inc, Kowa Co Ltd and Ensemble Therapeutics Corp, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Proprotein Convertase Subtilisin & Kexin Type 9, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Proprotein Convertase Subtilisin & Kexin Type 9.
The Proprotein Convertase Subtilisin & Kexin Type 9 market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Proprotein Convertase Subtilisin & Kexin Type 9 market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Proprotein Convertase Subtilisin & Kexin Type 9 Segment by Company
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Novartis AG
Eli Lilly and Co
Pfizer Inc
The Medicines Company
Serometrix LLC
Regeneron Pharmaceuticals Inc
Kowa Co Ltd
Ensemble Therapeutics Corp
Dicerna Pharmaceuticals Inc
Catabasis Pharmaceuticals Inc
BioLingus AG
Bioleaders Corp
Betagenon AB
AFFiRiS AG
Proprotein Convertase Subtilisin & Kexin Type 9 Segment by Type
SX-PCK9
O-304
K-312
DCRPCSK-9
BLSM-201
Others
Proprotein Convertase Subtilisin & Kexin Type 9 Segment by Application
Cardiovascular Disease
Homozugous Familial Hyperchalesterolemia
Liver Disease
Metabolic Syndrome
Others
Proprotein Convertase Subtilisin & Kexin Type 9 Segment by Application
Cardiovascular Disease
Homozugous Familial Hyperchalesterolemia
Liver Disease
Metabolic Syndrome
Others
Proprotein Convertase Subtilisin & Kexin Type 9 Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Proprotein Convertase Subtilisin & Kexin Type 9 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Proprotein Convertase Subtilisin & Kexin Type 9 and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Proprotein Convertase Subtilisin & Kexin Type 9.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Proprotein Convertase Subtilisin & Kexin Type 9 companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
According to APO Research, The global Proprotein Convertase Subtilisin & Kexin Type 9 market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Proprotein Convertase Subtilisin & Kexin Type 9 is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Proprotein Convertase Subtilisin & Kexin Type 9 is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Proprotein Convertase Subtilisin & Kexin Type 9 is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Proprotein Convertase Subtilisin & Kexin Type 9 include Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, Novartis AG, Eli Lilly and Co, Pfizer Inc, The Medicines Company, Serometrix LLC, Regeneron Pharmaceuticals Inc, Kowa Co Ltd and Ensemble Therapeutics Corp, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Proprotein Convertase Subtilisin & Kexin Type 9, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Proprotein Convertase Subtilisin & Kexin Type 9.
The Proprotein Convertase Subtilisin & Kexin Type 9 market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Proprotein Convertase Subtilisin & Kexin Type 9 market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Proprotein Convertase Subtilisin & Kexin Type 9 Segment by Company
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Novartis AG
Eli Lilly and Co
Pfizer Inc
The Medicines Company
Serometrix LLC
Regeneron Pharmaceuticals Inc
Kowa Co Ltd
Ensemble Therapeutics Corp
Dicerna Pharmaceuticals Inc
Catabasis Pharmaceuticals Inc
BioLingus AG
Bioleaders Corp
Betagenon AB
AFFiRiS AG
Proprotein Convertase Subtilisin & Kexin Type 9 Segment by Type
SX-PCK9
O-304
K-312
DCRPCSK-9
BLSM-201
Others
Proprotein Convertase Subtilisin & Kexin Type 9 Segment by Application
Cardiovascular Disease
Homozugous Familial Hyperchalesterolemia
Liver Disease
Metabolic Syndrome
Others
Proprotein Convertase Subtilisin & Kexin Type 9 Segment by Application
Cardiovascular Disease
Homozugous Familial Hyperchalesterolemia
Liver Disease
Metabolic Syndrome
Others
Proprotein Convertase Subtilisin & Kexin Type 9 Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Proprotein Convertase Subtilisin & Kexin Type 9 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Proprotein Convertase Subtilisin & Kexin Type 9 and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Proprotein Convertase Subtilisin & Kexin Type 9.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Proprotein Convertase Subtilisin & Kexin Type 9 companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
Table of Contents
130 Pages
- 1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
- 2 Market Overview
- 2.1 Product Definition
- 2.2 Proprotein Convertase Subtilisin & Kexin Type 9 by Type
- 2.2.1 Market Value Comparison by Type (2020 VS 2024 VS 2031)
- 2.2.2 SX-PCK9
- 2.2.3 O-304
- 2.2.4 K-312
- 2.2.5 DCRPCSK-9
- 2.2.6 BLSM-201
- 2.2.7 Others
- 2.3 Proprotein Convertase Subtilisin & Kexin Type 9 by Application
- 2.3.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
- 2.3.2 Cardiovascular Disease
- 2.3.3 Homozugous Familial Hyperchalesterolemia
- 2.3.4 Liver Disease
- 2.3.5 Metabolic Syndrome
- 2.3.6 Others
- 2.4 Assumptions and Limitations
- 3 Proprotein Convertase Subtilisin & Kexin Type 9 Breakdown Data by Type
- 3.1 Global Proprotein Convertase Subtilisin & Kexin Type 9 Historic Market Size by Type (2020-2025)
- 3.2 Global Proprotein Convertase Subtilisin & Kexin Type 9 Forecasted Market Size by Type (2026-2031)
- 4 Proprotein Convertase Subtilisin & Kexin Type 9 Breakdown Data by Application
- 4.1 Global Proprotein Convertase Subtilisin & Kexin Type 9 Historic Market Size by Application (2020-2025)
- 4.2 Global Proprotein Convertase Subtilisin & Kexin Type 9 Forecasted Market Size by Application (2026-2031)
- 5 Global Growth Trends
- 5.1 Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Perspective (2020-2031)
- 5.2 Global Proprotein Convertase Subtilisin & Kexin Type 9 Growth Trends by Region
- 5.2.1 Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Region: 2020 VS 2024 VS 2031
- 5.2.2 Proprotein Convertase Subtilisin & Kexin Type 9 Historic Market Size by Region (2020-2025)
- 5.2.3 Proprotein Convertase Subtilisin & Kexin Type 9 Forecasted Market Size by Region (2026-2031)
- 5.3 Proprotein Convertase Subtilisin & Kexin Type 9 Market Dynamics
- 5.3.1 Proprotein Convertase Subtilisin & Kexin Type 9 Industry Trends
- 5.3.2 Proprotein Convertase Subtilisin & Kexin Type 9 Market Drivers
- 5.3.3 Proprotein Convertase Subtilisin & Kexin Type 9 Market Challenges
- 5.3.4 Proprotein Convertase Subtilisin & Kexin Type 9 Market Restraints
- 6 Market Competitive Landscape by Players
- 6.1 Global Top Proprotein Convertase Subtilisin & Kexin Type 9 Players by Revenue
- 6.1.1 Global Top Proprotein Convertase Subtilisin & Kexin Type 9 Players by Revenue (2020-2025)
- 6.1.2 Global Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Market Share by Players (2020-2025)
- 6.2 Global Proprotein Convertase Subtilisin & Kexin Type 9 Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Proprotein Convertase Subtilisin & Kexin Type 9 Head Office and Area Served
- 6.4 Global Proprotein Convertase Subtilisin & Kexin Type 9 Players, Product Type & Application
- 6.5 Global Proprotein Convertase Subtilisin & Kexin Type 9 Manufacturers Established Date
- 6.6 Global Proprotein Convertase Subtilisin & Kexin Type 9 Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
- 7 North America
- 7.1 North America Proprotein Convertase Subtilisin & Kexin Type 9 Market Size (2020-2031)
- 7.2 North America Proprotein Convertase Subtilisin & Kexin Type 9 Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 7.3 North America Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Country (2020-2025)
- 7.4 North America Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Country (2026-2031)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
- 8 Europe
- 8.1 Europe Proprotein Convertase Subtilisin & Kexin Type 9 Market Size (2020-2031)
- 8.2 Europe Proprotein Convertase Subtilisin & Kexin Type 9 Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 8.3 Europe Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Country (2020-2025)
- 8.4 Europe Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Country (2026-2031)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
- 9 Asia-Pacific
- 9.1 Asia-Pacific Proprotein Convertase Subtilisin & Kexin Type 9 Market Size (2020-2031)
- 9.2 Asia-Pacific Proprotein Convertase Subtilisin & Kexin Type 9 Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 9.3 Asia-Pacific Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Country (2020-2025)
- 9.4 Asia-Pacific Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Country (2026-2031)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
- 10 South America
- 10.1 South America Proprotein Convertase Subtilisin & Kexin Type 9 Market Size (2020-2031)
- 10.2 South America Proprotein Convertase Subtilisin & Kexin Type 9 Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 10.3 South America Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Country (2020-2025)
- 10.4 South America Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Country (2026-2031)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
- 11 Middle East & Africa
- 11.1 Middle East & Africa Proprotein Convertase Subtilisin & Kexin Type 9 Market Size (2020-2031)
- 11.2 Middle East & Africa Proprotein Convertase Subtilisin & Kexin Type 9 Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 11.3 Middle East & Africa Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Country (2020-2025)
- 11.4 Middle East & Africa Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Country (2026-2031)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
- 12 Players Profiled
- 12.1 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
- 12.1.1 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Company Information
- 12.1.2 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Business Overview
- 12.1.3 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2020-2025)
- 12.1.4 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
- 12.1.5 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Recent Developments
- 12.2 Novartis AG
- 12.2.1 Novartis AG Company Information
- 12.2.2 Novartis AG Business Overview
- 12.2.3 Novartis AG Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2020-2025)
- 12.2.4 Novartis AG Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
- 12.2.5 Novartis AG Recent Developments
- 12.3 Eli Lilly and Co
- 12.3.1 Eli Lilly and Co Company Information
- 12.3.2 Eli Lilly and Co Business Overview
- 12.3.3 Eli Lilly and Co Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2020-2025)
- 12.3.4 Eli Lilly and Co Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
- 12.3.5 Eli Lilly and Co Recent Developments
- 12.4 Pfizer Inc
- 12.4.1 Pfizer Inc Company Information
- 12.4.2 Pfizer Inc Business Overview
- 12.4.3 Pfizer Inc Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2020-2025)
- 12.4.4 Pfizer Inc Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
- 12.4.5 Pfizer Inc Recent Developments
- 12.5 The Medicines Company
- 12.5.1 The Medicines Company Company Information
- 12.5.2 The Medicines Company Business Overview
- 12.5.3 The Medicines Company Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2020-2025)
- 12.5.4 The Medicines Company Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
- 12.5.5 The Medicines Company Recent Developments
- 12.6 Serometrix LLC
- 12.6.1 Serometrix LLC Company Information
- 12.6.2 Serometrix LLC Business Overview
- 12.6.3 Serometrix LLC Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2020-2025)
- 12.6.4 Serometrix LLC Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
- 12.6.5 Serometrix LLC Recent Developments
- 12.7 Regeneron Pharmaceuticals Inc
- 12.7.1 Regeneron Pharmaceuticals Inc Company Information
- 12.7.2 Regeneron Pharmaceuticals Inc Business Overview
- 12.7.3 Regeneron Pharmaceuticals Inc Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2020-2025)
- 12.7.4 Regeneron Pharmaceuticals Inc Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
- 12.7.5 Regeneron Pharmaceuticals Inc Recent Developments
- 12.8 Kowa Co Ltd
- 12.8.1 Kowa Co Ltd Company Information
- 12.8.2 Kowa Co Ltd Business Overview
- 12.8.3 Kowa Co Ltd Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2020-2025)
- 12.8.4 Kowa Co Ltd Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
- 12.8.5 Kowa Co Ltd Recent Developments
- 12.9 Ensemble Therapeutics Corp
- 12.9.1 Ensemble Therapeutics Corp Company Information
- 12.9.2 Ensemble Therapeutics Corp Business Overview
- 12.9.3 Ensemble Therapeutics Corp Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2020-2025)
- 12.9.4 Ensemble Therapeutics Corp Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
- 12.9.5 Ensemble Therapeutics Corp Recent Developments
- 12.10 Dicerna Pharmaceuticals Inc
- 12.10.1 Dicerna Pharmaceuticals Inc Company Information
- 12.10.2 Dicerna Pharmaceuticals Inc Business Overview
- 12.10.3 Dicerna Pharmaceuticals Inc Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2020-2025)
- 12.10.4 Dicerna Pharmaceuticals Inc Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
- 12.10.5 Dicerna Pharmaceuticals Inc Recent Developments
- 12.11 Catabasis Pharmaceuticals Inc
- 12.11.1 Catabasis Pharmaceuticals Inc Company Information
- 12.11.2 Catabasis Pharmaceuticals Inc Business Overview
- 12.11.3 Catabasis Pharmaceuticals Inc Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2020-2025)
- 12.11.4 Catabasis Pharmaceuticals Inc Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
- 12.11.5 Catabasis Pharmaceuticals Inc Recent Developments
- 12.12 BioLingus AG
- 12.12.1 BioLingus AG Company Information
- 12.12.2 BioLingus AG Business Overview
- 12.12.3 BioLingus AG Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2020-2025)
- 12.12.4 BioLingus AG Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
- 12.12.5 BioLingus AG Recent Developments
- 12.13 Bioleaders Corp
- 12.13.1 Bioleaders Corp Company Information
- 12.13.2 Bioleaders Corp Business Overview
- 12.13.3 Bioleaders Corp Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2020-2025)
- 12.13.4 Bioleaders Corp Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
- 12.13.5 Bioleaders Corp Recent Developments
- 12.14 Betagenon AB
- 12.14.1 Betagenon AB Company Information
- 12.14.2 Betagenon AB Business Overview
- 12.14.3 Betagenon AB Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2020-2025)
- 12.14.4 Betagenon AB Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
- 12.14.5 Betagenon AB Recent Developments
- 12.15 AFFiRiS AG
- 12.15.1 AFFiRiS AG Company Information
- 12.15.2 AFFiRiS AG Business Overview
- 12.15.3 AFFiRiS AG Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2020-2025)
- 12.15.4 AFFiRiS AG Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
- 12.15.5 AFFiRiS AG Recent Developments
- 13 Report Conclusion
- 14 Disclaimer
- List of Tables
- Table 1. Secondary Sources
- Table 2. Primary Sources
- Table 3. Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
- Table 4. Market Value Comparison by Application (2020 VS 2024 VS 2031) & (US$ Million)
- Table 5. Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Type (2020-2025) & (US$ Million)
- Table 6. Global Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Market Share by Type (2020-2025)
- Table 7. Global Proprotein Convertase Subtilisin & Kexin Type 9 Forecasted Market Size by Type (2026-2031) & (US$ Million)
- Table 8. Global Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Market Share by Type (2026-2031)
- Table 9. Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Application (2020-2025) & (US$ Million)
- Table 10. Global Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Market Share by Application (2020-2025)
- Table 11. Global Proprotein Convertase Subtilisin & Kexin Type 9 Forecasted Market Size by Application (2026-2031) & (US$ Million)
- Table 12. Global Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Market Share by Application (2026-2031)
- Table 13. Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
- Table 14. Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Region (2020-2025) & (US$ Million)
- Table 15. Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Share by Region (2020-2025)
- Table 16. Global Proprotein Convertase Subtilisin & Kexin Type 9 Forecasted Market Size by Region (2026-2031) & (US$ Million)
- Table 17. Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Share by Region (2026-2031)
- Table 18. Proprotein Convertase Subtilisin & Kexin Type 9 Industry Trends
- Table 19. Proprotein Convertase Subtilisin & Kexin Type 9 Industry Drivers
- Table 20. Proprotein Convertase Subtilisin & Kexin Type 9 Industry Opportunities and Challenges
- Table 21. Proprotein Convertase Subtilisin & Kexin Type 9 Market Restraints
- Table 22. Global Top Proprotein Convertase Subtilisin & Kexin Type 9 Players by Revenue (US$ Million) & (2020-2025)
- Table 23. Global Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Market Share by Players (2020-2025)
- Table 24. Global Proprotein Convertase Subtilisin & Kexin Type 9 Industry Players Ranking, 2023 VS 2024 VS 2025
- Table 25. Global Key Players of Proprotein Convertase Subtilisin & Kexin Type 9, Headquarters and Area Served
- Table 26. Global Proprotein Convertase Subtilisin & Kexin Type 9 Players, Product Type & Application
- Table 27. Global Players Market Concentration Ratio (CR5 and HHI)
- Table 28. Global Proprotein Convertase Subtilisin & Kexin Type 9 by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2024)
- Table 29. Players Mergers & Acquisitions, Expansion Plans
- Table 30. North America Proprotein Convertase Subtilisin & Kexin Type 9 Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 31. North America Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Country (2020-2025) & (US$ Million)
- Table 32. North America Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Country (2026-2031) & (US$ Million)
- Table 33. Europe Proprotein Convertase Subtilisin & Kexin Type 9 Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 34. Europe Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Country (2020-2025) & (US$ Million)
- Table 35. Europe Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Country (2026-2031) & (US$ Million)
- Table 36. Asia Pacific Proprotein Convertase Subtilisin & Kexin Type 9 Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 37. Asia Pacific Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Region (2020-2025) & (US$ Million)
- Table 38. Asia Pacific Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Country (2026-2031) & (US$ Million)
- Table 39. South America Proprotein Convertase Subtilisin & Kexin Type 9 Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 40. South America Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Country (2020-2025) & (US$ Million)
- Table 41. South America Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Country (2026-2031) & (US$ Million)
- Table 42. Middle East & Africa Proprotein Convertase Subtilisin & Kexin Type 9 Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 43. Middle East & Africa Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Country (2020-2025) & (US$ Million)
- Table 44. Middle East & Africa Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Country (2026-2031) & (US$ Million)
- Table 45. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Company Information
- Table 46. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Business Overview
- Table 47. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2020-2025) & (US$ Million)
- Table 48. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
- Table 49. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Recent Developments
- Table 50. Novartis AG Company Information
- Table 51. Novartis AG Business Overview
- Table 52. Novartis AG Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2020-2025) & (US$ Million)
- Table 53. Novartis AG Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
- Table 54. Novartis AG Recent Developments
- Table 55. Eli Lilly and Co Company Information
- Table 56. Eli Lilly and Co Business Overview
- Table 57. Eli Lilly and Co Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2020-2025) & (US$ Million)
- Table 58. Eli Lilly and Co Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
- Table 59. Eli Lilly and Co Recent Developments
- Table 60. Pfizer Inc Company Information
- Table 61. Pfizer Inc Business Overview
- Table 62. Pfizer Inc Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2020-2025) & (US$ Million)
- Table 63. Pfizer Inc Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
- Table 64. Pfizer Inc Recent Developments
- Table 65. The Medicines Company Company Information
- Table 66. The Medicines Company Business Overview
- Table 67. The Medicines Company Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2020-2025) & (US$ Million)
- Table 68. The Medicines Company Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
- Table 69. The Medicines Company Recent Developments
- Table 70. Serometrix LLC Company Information
- Table 71. Serometrix LLC Business Overview
- Table 72. Serometrix LLC Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2020-2025) & (US$ Million)
- Table 73. Serometrix LLC Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
- Table 74. Serometrix LLC Recent Developments
- Table 75. Regeneron Pharmaceuticals Inc Company Information
- Table 76. Regeneron Pharmaceuticals Inc Business Overview
- Table 77. Regeneron Pharmaceuticals Inc Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2020-2025) & (US$ Million)
- Table 78. Regeneron Pharmaceuticals Inc Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
- Table 79. Regeneron Pharmaceuticals Inc Recent Developments
- Table 80. Kowa Co Ltd Company Information
- Table 81. Kowa Co Ltd Business Overview
- Table 82. Kowa Co Ltd Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2020-2025) & (US$ Million)
- Table 83. Kowa Co Ltd Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
- Table 84. Kowa Co Ltd Recent Developments
- Table 85. Ensemble Therapeutics Corp Company Information
- Table 86. Ensemble Therapeutics Corp Business Overview
- Table 87. Ensemble Therapeutics Corp Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2020-2025) & (US$ Million)
- Table 88. Ensemble Therapeutics Corp Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
- Table 89. Ensemble Therapeutics Corp Recent Developments
- Table 90. Dicerna Pharmaceuticals Inc Company Information
- Table 91. Dicerna Pharmaceuticals Inc Business Overview
- Table 92. Dicerna Pharmaceuticals Inc Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2020-2025) & (US$ Million)
- Table 93. Dicerna Pharmaceuticals Inc Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
- Table 94. Dicerna Pharmaceuticals Inc Recent Developments
- Table 95. Catabasis Pharmaceuticals Inc Company Information
- Table 96. Catabasis Pharmaceuticals Inc Business Overview
- Table 97. Catabasis Pharmaceuticals Inc Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2020-2025) & (US$ Million)
- Table 98. Catabasis Pharmaceuticals Inc Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
- Table 99. Catabasis Pharmaceuticals Inc Recent Developments
- Table 100. BioLingus AG Company Information
- Table 101. BioLingus AG Business Overview
- Table 102. BioLingus AG Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2020-2025) & (US$ Million)
- Table 103. BioLingus AG Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
- Table 104. BioLingus AG Recent Developments
- Table 105. Bioleaders Corp Company Information
- Table 106. Bioleaders Corp Business Overview
- Table 107. Bioleaders Corp Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2020-2025) & (US$ Million)
- Table 108. Bioleaders Corp Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
- Table 109. Bioleaders Corp Recent Developments
- Table 110. Betagenon AB Company Information
- Table 111. Betagenon AB Business Overview
- Table 112. Betagenon AB Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2020-2025) & (US$ Million)
- Table 113. Betagenon AB Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
- Table 114. Betagenon AB Recent Developments
- Table 115. AFFiRiS AG Company Information
- Table 116. AFFiRiS AG Business Overview
- Table 117. AFFiRiS AG Revenue in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2020-2025) & (US$ Million)
- Table 118. AFFiRiS AG Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
- Table 119. AFFiRiS AG Recent Developments
- Table 120. Authors List of This Report
- List of Figures
- Figure 1. Research Methodology
- Figure 2. Research Process
- Figure 3. Key Executives Interviewed
- Figure 4. Proprotein Convertase Subtilisin & Kexin Type 9 Product Image
- Figure 5. Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Size Comparison by Type (2025-2031) & (US$ Million)
- Figure 6. Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Share by Type: 2024 VS 2031
- Figure 7. SX-PCK9 Product
- Figure 8. O-304 Product
- Figure 9. K-312 Product
- Figure 10. DCRPCSK-9 Product
- Figure 11. BLSM-201 Product
- Figure 12. Others Product
- Figure 13. Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Application (2025-2031) & (US$ Million)
- Figure 14. Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Share by Application: 2024 VS 2031
- Figure 15. Cardiovascular Disease Product
- Figure 16. Homozugous Familial Hyperchalesterolemia Product
- Figure 17. Liver Disease Product
- Figure 18. Metabolic Syndrome Product
- Figure 19. Others Product
- Figure 20. Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Size (US$ Million), Year-over-Year: 2020-2031
- Figure 21. Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Size, (US$ Million), 2020 VS 2024 VS 2031
- Figure 22. Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Share by Region: 2024 VS 2031
- Figure 23. Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Share by Players in 2024
- Figure 24. Global Proprotein Convertase Subtilisin & Kexin Type 9 Manufacturers Established Date
- Figure 25. Global Top 5 and 10 Proprotein Convertase Subtilisin & Kexin Type 9 Players Market Share by Revenue in 2024
- Figure 26. Players Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
- Figure 27. North America Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 28. North America Proprotein Convertase Subtilisin & Kexin Type 9 Market Share by Country (2020-2031)
- Figure 29. United States Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 30. Canada Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 31. Mexico Proprotein Convertase Subtilisin & Kexin Type 9 Market Share by Country (2020-2031)
- Figure 32. Europe Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 33. Europe Proprotein Convertase Subtilisin & Kexin Type 9 Market Share by Country (2020-2031)
- Figure 34. Germany Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 35. France Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 36. U.K. Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 37. Italy Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 38. Spain Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 39. Russia Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 40. Netherlands Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 41. Nordic Countries Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 42. Asia-Pacific Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 43. Asia-Pacific Proprotein Convertase Subtilisin & Kexin Type 9 Market Share by Country (2020-2031)
- Figure 44. China Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 45. Japan Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 46. South Korea Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 47. India Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 48. India Proprotein Convertase Subtilisin & Kexin Type 9 Market Share by Country (2020-2031)
- Figure 49. Australia Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 50. China Taiwan Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 51. Southeast Asia Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 52. South America Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 53. South America Proprotein Convertase Subtilisin & Kexin Type 9 Market Share by Country (2020-2031)
- Figure 54. Brazil Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 55. Argentina Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 56. Chile Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 57. Colombia Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 58. Peru Proprotein Convertase Subtilisin & Kexin Type 9 Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 59. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Revenue Growth Rate in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2020-2025)
- Figure 60. Novartis AG Revenue Growth Rate in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2020-2025)
- Figure 61. Eli Lilly and Co Revenue Growth Rate in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2020-2025)
- Figure 62. Pfizer Inc Revenue Growth Rate in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2020-2025)
- Figure 63. The Medicines Company Revenue Growth Rate in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2020-2025)
- Figure 64. Serometrix LLC Revenue Growth Rate in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2020-2025)
- Figure 65. Regeneron Pharmaceuticals Inc Revenue Growth Rate in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2020-2025)
- Figure 66. Kowa Co Ltd Revenue Growth Rate in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2020-2025)
- Figure 67. Ensemble Therapeutics Corp Revenue Growth Rate in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2020-2025)
- Figure 68. Dicerna Pharmaceuticals Inc Revenue Growth Rate in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2020-2025)
- Figure 69. Catabasis Pharmaceuticals Inc Revenue Growth Rate in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2020-2025)
- Figure 70. BioLingus AG Revenue Growth Rate in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2020-2025)
- Figure 71. Bioleaders Corp Revenue Growth Rate in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2020-2025)
- Figure 72. Betagenon AB Revenue Growth Rate in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2020-2025)
- Figure 73. AFFiRiS AG Revenue Growth Rate in Proprotein Convertase Subtilisin & Kexin Type 9 Business (2020-2025)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.


